You are currently viewing Biomatrix Features Relevant to Bifurcational Stenting and the LEADERS Bifurcation Substudy

Biomatrix Features Relevant to Bifurcational Stenting and the LEADERS Bifurcation Substudy

EBC - ON DEMAND

Biomatrix Features Relevant to Bifurcational Stenting and the LEADERS Bifurcation Substudy

European Bifurcation Club 2010 – EBC 2010 – Budapest, Hungary

New DES and bifurcation stenting

Biomatrix Features Relevant to Bifurcational Stenting and the LEADERS Bifurcation Substudy

Author: Carlo Di Mario, Nicolas Foin, Imperial College London, UK

 

BIOLIMUS A9 ELUTING BIOMATRIX STENT

  • Biolimus is a semi-synthetic sirolimus analogue with 10x higher lipophilicity and similar potency as sirolimus.
  • Biolimus is immersed into a biodegradable polymer, polylactic acid, and applied solely to the abluminal stent surface
  • Biolimus is co-released with polylactic acid that completely desolves into carbon dioxide and water after a 6-9 months period.
  • The same coating and drug has been successfully used in bifurcational trials with the dedicated self- expanding DEVAX platform
  • The stainless steel stent platform has a strut thickness of 120 μm with a quadrature link design.

CONCLUSION

  • The Biomatrix Flex stent offers a large opening when dilated through the struts, sufficient to fit almost all coronary anatomies
  • Biolimus eluting stent appears to offer an advantage in treating patients with bifurcational lesions
  • Larger cohorts of prospectively collected data as well as mechanistic insights are needed to confirm these findings.

 

DOWNLOAD HERE

Leave a Reply